Featured Content

Our Update on COVID-19

Latest Press Releases

Apr 02, 2020 Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Mar 31, 2020 TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Mar 26, 2020 Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities

See All Press Releases

Featured Videos

The Horizon Story

The Horizon Story

Going to Incredible Lengths: Buck Miller

Going to Incredible Lengths: Buck Miller

#RAREis: Francis’ Rare Disease Adoption Story in Song

#RAREis: Francis’ Rare Disease Adoption Story in Song

Giving Back is Personal

Giving Back is Personal

Fact Sheets & Downloads

See All Fact Sheets

Logo Download

Download Horizon Logo | RGB Full Color (.jpg)
Download Horizon Logo | RGB Full Color (.png)
Download Horizon Logo | Charcoal Single Color (.jpg)
Download Horizon Logo | Charcoal Single Color (.png)

If you are looking for additional Horizon media assets, please contact corporatecommunications@horizontherapeutics.com

Media Inquiries

For U.S. media inquiries, contact:
Geoff Curtis
Senior Vice President, Corporate Affairs
media@horizontherapeutics.com
+1 (888) 506-2562

For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373